Given these findings, numerous studies have explored the efficacy of the combination of EGFR-TKIs with MET-TKIs in advanced NSCLC patients harboring secondary MET amplification, achieving satisfactory therapeutic outcomes. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.